このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ヒーリーALSマイマッチ共通スクリーニングプロトコル (MCSP)

2026年11月9日 更新者:Suma Babu、Massachusetts General Hospital

ALS MyMatch早期段階臨床試験の予備適格性を判断するためのHealey ALS MyMatch共通スクリーニングプロトコル(MCSP)

The Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.

People who complete an MCSP Screening Visit will undergo:

  • clinical assessments
  • laboratory testing
  • biomarker analyses

The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.

調査の概要

詳細な説明

The MyMatch Common Screening Protocol (MCSP) is an observational study that is part of the Healey ALS MyMatch program. Healey ALS MyMatch is an early phase (Phase 1b or 2a), Amyotrophic Lateral Sclerosis (ALS) clinical trial program. ALS MyMatch is designed to help match adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.

The first step in participating in Healey ALS MyMatch is to complete a screening visit for the MCSP. MCSP screening visit activities can be completed over a period of 45-days and some screening visit activities can be completed remotely. MCSP screening visit activities include:

  • obtaining informed consent
  • reviewing medical history
  • collecting blood samples
  • completing a 12-lead ECG
  • completing questionnaires

To be eligible to participate in the MCSP, the following key criteria will need to be met: ALS diagnosis, SVC breathing score of equal to or greater than 65%, and ALS genetic testing.

The information collected at the MCSP screening visit helps researchers determine whether a participant might qualify for one or more treatment studies that are currently enrolling in the ALS MyMatch program. If a participant appears eligible for more than one study, then the participant may choose to consult with their doctor and decide which study would be a better fit for them.

研究の種類

観察的

入学 (推定)

500

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Healey ALS MyMatch Clinical Operations Team
  • 電話番号:857-282-9210
  • メール:mghalsmymatch@mgb.org

研究場所

    • Florida
      • Davie、Florida、アメリカ、33314
        • まだ募集していません
        • Nova Southeastern University
        • コンタクト:
    • Illinois
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • 募集
        • Massachusetts General Hospital
        • コンタクト:
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55414
        • まだ募集していません
        • University of Minnesota
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

The target populations for MCSP and ALS MyMatch trials will initially focus on subgroups of individuals with ALS, including those with early-stage disease. Some ALS MyMatch trials will further target those with specific biomarkers or genetic markers for inclusion in a specific trial.

説明

Inclusion Criteria:

  1. Ability to provide written informed consent.
  2. Adults > 18 years of age.
  3. Diagnosis of symptomatic ALS that meets either the revised El Escorial Criteria.(clinically possible, probable, probable lab-supported, or definite) or the Gold Coast Criteria.
  4. Available or pending clinically obtained CLIA ALS genetic panel report.
  5. Time since onset of weakness due to ALS ≤ 24 months at the time of MCSP screening.
  6. Slow VC ≥ 65% of predicted capacity value for gender, height and age at screening.
  7. Clinically unremarkable Complete Blood Counts as per SI's discretion, including but not limited to Hemoglobin ≥ 9 g/dL.
  8. Ability and willingness to complete all study procedures per SI's assessment.
  9. Negative pregnancy test at screening for women of child-bearing potential (WOCB), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).

Exclusion Criteria:

  1. Clinically significant unstable medical or surgical condition that would pose a risk to the participant's trial procedural participation or interfere with data collection, per SI's assessment.

  2. Presence of cognitive or mental health disorders impairing ability to provide informed consent for the study per SI assessment.

  3. Active cancer or history of cancer, unless it was successfully treated for durable remission or cure more than 3 years ago. (Note that basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies that have been curatively excised at any time previously and with no evidence of disease recurrence for at least 3 years are not exclusionary.)

  4. Prior solid organ transplantation.

  5. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the MCSP Screening Visit. (Please refer to the Manual of Procedures (MOP) for current list of experimental therapies)

  6. Screening 12-lead ECG showing QT interval corrected for rate (QTcF) > 470 msec for women and > 450 msec for men, absence of second degree or higher AV block or other clinically significant cardiac arrythmias.

  7. Clinically significant abnormalities in the Comprehensive Metabolic Panel per SI's assessment, including but not limited to:

    1. Serum alanine aminotransferase or aspartate aminotransferase > 3 times the upper limit of normal, or serum bilirubin > 1.5 × upper limit of normal
    2. Estimated GFR (eGFR) of < 30 mL/min/1.73m2
  8. Other clinically significant electrolyte and metabolic abnormalities

  9. If female, breastfeeding, pregnant, or of child-bearing potential and unwilling to use effective contraception for duration of the trial and after discontinuing treatment as outlined in the ALS MyMatch trial protocol.

  10. Clinically significant unstable medical conditions (other than ALS) that would pose a risk to the participant, per SI's assessment (e.g., cardiovascular instability, systemic infection,), or clinically significant laboratory abnormality or ECG changes.

  11. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).

  12. Participants who require Permanent assisted ventilation (PAV). PAV defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Preliminary eligibility to be matched to a MyMatch Trial
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.

To determine preliminary eligibility of early ALS (< 24 months from weakness onset) participants for actively enrolling ALS MyMatch trial(s)

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.

二次結果の測定

結果測定
メジャーの説明
時間枠
Repository for future research
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

To build an ALS biofluid, genetic and data repository for future clinical and translational research.

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
Prevalence of gene mutations
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

To characterize the prevalence of participants with causative or risk modifier gene mutations in the MCSP

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
Collect and bank samples
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

To collect and bank blood samples for future biofluid biomarker analyses

From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年8月31日

一次修了 (推定)

2029年3月16日

研究の完了 (推定)

2029年3月16日

試験登録日

最初に提出

2026年1月29日

QC基準を満たした最初の提出物

2026年2月6日

最初の投稿 (実際)

2026年2月10日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年10月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する